IC
SANA icon

Ikarian Capital’s Sana Biotechnology SANA Stock Holding History

Ikarian Capital’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-650,000
Closed -$1.06M – 208
2024
Q4 		$1.06M Hold
650,000
– – 0.14% 106
2024
Q3 		$2.7M Buy
650,000
+646,000
+16,150% +$3.39M 0.38% 66
2024
Q2 		$2.18M Buy
+4,000
New +$31.9K 0.38% 54

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's SANA Position: Q1 2025 in Review

Ikarian Capital sold out of Sana Biotechnology (SANA) in Q1 2025, closing a stake of 365,000 shares — an estimated $595K sold.

Ikarian Capital first reported a position in SANA in Q4 2024 and held it in 1 quarter. The position peaked at $595K in Q4 2024. 161 funds tracked by Wall St. Rank hold SANA as of Q1 2025.

  • Ikarian Capital reported no remaining Sana Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 365,000 Sana Biotechnology shares in Q1 2025, an estimated $595K.
  • Ikarian Capital first reported a position in Sana Biotechnology in Q4 2024 and held it in 1 quarter.
  • Ikarian Capital's Sana Biotechnology position peaked at $595K in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.